Buy Alunbrig Online

(Brigatinib)

The active ingredient in Alunbrig is brigatinib.

Brigatinib is an ALK inhibitor that targets abnormal proteins caused by mutations in the ALK gene.

The mechanism of action includes:

• Blocking the activity of the ALK protein in cancer cells.
• Preventing cancer cell growth and division.
• Slowing disease progression in ALK-positive NSCLC.

This targeted approach helps treat metastatic NSCLC, including cases with brain metastases.

Follow all directions given to you by your doctor and read all documents provided, including the full Prescribing Information, FDA-Approved Product Labeling, Instructions for Use, and Medication Guide before using Alunbrig. However, the following is a synopsis of the general guidelines for the use of Alunbrig:

• Take Alunbrig exactly as prescribed by your healthcare provider.
• Take the medication once daily, with or without food.
• Swallow tablets whole with water.
• Do not crush or chew the tablets.
• A lower starting dose is often used during the first week, followed by an increased dose if tolerated.
• Continue treatment until disease progression or unacceptable toxicity occurs.
• Regular monitoring is required during treatment to assess response and side effects.

Some mild or common side effects of Alunbrig seen in clinical trials include:

• Nausea.
• Diarrhea.
• Fatigue.
• Headache.
• Muscle pain (myalgia).
• Abnormal liver enzymes.
• Rash.
• Cough.
• Headache.

Some individuals may experience serious side effects while using Alunbrig. These side effects may require immediate medical attention. If you experience any of the following, contact your healthcare provider or seek emergency medical help:

• Lung problems such as pneumonitis or shortness of breath (dyspnea).
• High blood pressure (hypertension).
• Slow heart rate (bradycardia).
• High blood sugar (hyperglycemia).
• Muscle damage with increased creatine phosphokinase (CPK).
• Vision problems or visual disturbances.
• Serious hepatic impairment.

These are not all of the possible side effects of Alunbrig. You should always seek medical advice from your healthcare provider for any questions or concerns about your medical condition or treatment. Read all patient information, medication guides, or drug information sheets that come with this medication. You can also report adverse effects to the Food and Drug Administration at www.fda.gov/medwatch or 1-800-FDA-1088.

Before starting Alunbrig, it is crucial to discuss any existing health conditions with your healthcare provider. You should be sure that your healthcare provider is aware of all your medical conditions, including if you have:

• Lung disease or breathing problems, which can be life-threatening.
• Seek help immediately for new or worsening shortness of breath, chest pain, or fever.
• High blood pressure or heart problems.
• Diabetes or high blood sugar.
• Liver or renal impairment.
• A history of muscle disorders.

Alunbrig may increase enzymes in your blood called amylase and lipase, which may be a sign of pancreatitis.

Alunbrig may cause serious lung toxicity, especially early in treatment.

Patients should be monitored for blood pressure, glucose levels, and muscle enzyme levels during therapy.

Advise males with female partners of reproductive potential to use effective contraception during treatment.

Alunbrig should not be used in patients who have:

Adverse reactions to brigatinib or any component of the formulation.

Your healthcare provider will determine if this medication is appropriate for your condition.

Alunbrig may begin to work within weeks, but full clinical benefit may take longer, depending on the patient.

Response to treatment is monitored through imaging and clinical evaluation.

When Alunbrig is taken with other prescription drugs, over-the-counter medications, vitamins, and supplements, it may change how they work or increase the frequency or severity of side effects. Make sure that you tell your healthcare professional about anything that you are taking to avoid any negative drug interactions, including:

• CYP3A inhibitors, which may increase brigatinib levels and toxicity.
• CYP3A inducers, which may reduce effectiveness by lowering drug levels.
• Grapefruit juice, which may increase drug exposure.
• Healthcare providers may adjust dosing or avoid coadministration combinations.

Alunbrig is available as oral tablets in different strengths.

Typical dose of Alunbrig includes:

• A lower dose for the first week.
• An increased maintenance dose if tolerated.

Dose adjustment depends on patient tolerance and clinical response.

It should be stored at room temperature, away from the reach of children or pets.

Alunbrig is manufactured by Takeda Pharmaceutical Company Limited.

There is currently no widely available generic version of brigatinib.

Do not stop taking Alunbrig without consulting your healthcare provider. Treatment decisions should be made based on disease progression and tolerance.

Alunbrig may harm an unborn baby, and effective contraception is recommended during treatment and for at least 3 months after the final dose.

Talk to your doctor if you are already breastfeeding or if you have any plans to breastfeed. Breastfeeding is not recommended during treatment due to potential risks.